|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 34.2 TWD | -0.44% |
|
+3.17% | -8.80% |
| Mar. 13 | Enimmune corporation Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 2023 | Enimmune corporation Reports Earnings Results for the Half Year Ended June 30, 2023 | CI |
Enimmune corporation reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was TWD 43.49 million compared to TWD 188.42 million a year ago. Net loss was TWD 223.74 million compared to TWD 247.96 million a year ago.
Basic loss per share from continuing operations was TWD 3.4 compared to TWD 3.88 a year ago. Diluted loss per share from continuing operations was TWD 3.4 compared to TWD 3.88 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -8.80% | 68.99M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
ENIMMUNE CORPORATION 
